Company Encyclopedia
View More
name
BioCardia
BCDA.US
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products.
1.946 T
BCDA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking381/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-317.47%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY-10.59%D
    • Total Assets YoY-1.90%D
    • Net Assets YoY-4.58%D
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreD
    • Gearing Ratio57.27%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Biocardia Announces Election Of New Board Director

    Dec 3 (Reuters) - BioCardia Inc:* BIOCARDIA ANNOUNCES ELECTION OF NEW BOARD DIRECTOR, MARVIN SLOSMAN AND COMPLETION OF TERM FOR OUTGOING DIRECTOR, DR. RICHARD KRASNO Source text: Further company coverage:

    Reuters·
    US
    BCDA
    +3.52%
    Reuters·
    US
    BCDA
    +3.52%

    BioCardia Appoints Marvin Slosman to Board as Richard Krasno Departs

    BioCardia Inc. announced Marvin Slosman's election to its Board of Directors, effective December 2, 2025, as Richard Krasno departs after completing his term.

    Reuters·
    US
    BCDA
    +3.52%
    Reuters·
    US
    BCDA
    +3.52%

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality | BCDA Stock News

    BioCardia, Inc. has appointed Farhan Shahab as Vice President of Quality. Shahab brings over 25 years of experience in quality and regulatory roles from companies like Welldoc and Medtronic. His expertise is expected to enhance BioCardia's product commercialization efforts. CEO Peter Altman expressed confidence in Shahab's leadership and experience. BioCardia is a leader in cellular therapeutics for cardiovascular and pulmonary diseases.

    StockTitan·
    US
    BCDA
    +3.52%
    StockTitan·
    US
    BCDA
    +3.52%

    BioCardia’s Earnings Call: Progress Amid Financial Challenges

    BioCardia's Q3 earnings call highlighted significant clinical and regulatory advancements, including a positive consultation in Japan and FDA breakthrough designation for its CardiAmp system. Despite these achievements, the company faces financial challenges, reporting a net loss of $1.5 million. BioCardia is optimistic about securing non-dilutive funding and continues to focus on innovation and strategic growth, with key milestones anticipated in 2025 and 2026.

    Tip Ranks·
    US
    BCDA
    +3.52%
    Tip Ranks·
    US
    BCDA
    +3.52%

    BioCardia’s Strategic Advancements and Financial Stability Drive Buy Rating

    Joseph Pantginis from H.C. Wainwright maintained a Buy rating on BioCardia with a $25.00 price target. The rating is based on BioCardia's strategic advancements, regulatory milestones, and financial stability. The company is progressing with its CardiAMP HF program in the U.S. and Japan, and has a cash runway until Q2 2026. Despite past trial setbacks, ongoing trials like CardiAMP HF II and CardiALLO show promise. Pantginis has an average return of 2.2% and a 44.09% success rate on recommended stocks.

    Tip Ranks·
    US
    BCDA
    +3.52%
    Tip Ranks·
    US
    BCDA
    +3.52%
    © 2025 Longbridge｜Disclaimer